T helper 17 (Th17) cells produce interleukin-17 (IL-17) cytokines and drive inflammatory responses in autoimmune diseases such as multiple sclerosis. The differentiation of Th17 cells is dependent on the retinoic acid receptor-related orphan nuclear receptor RORγt. Here, we identify REV-ERBα (encoded by Nr1d1), a member of the nuclear hormone receptor family, as a transcriptional repressor that antagonizes RORγt function in Th17 cells. REV-ERBα binds to ROR response elements (RORE) in Th17 cells and inhibits the expression of RORγt-dependent genes including Il17a and Il17f. Furthermore, elevated REV-ERBα expression or treatment with a synthetic REV-ERB agonist significantly delays the onset and impedes the progression of experimental autoimmune encephalomyelitis (EAE). These results suggest that modulating REV-ERBα activity may be used to manipulate Th17 cells in autoimmune diseases.
transcriptional repressor | autoimmunity | nuclear receptors T helper 17 (Th17) cells are the drivers of inflammatory responses in a large number of autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, and psoriasis (1, 2) . The orphan nuclear receptor RORγt is the lineage-specific transcription factor that regulates the differentiation of Th17 cells (3) . RORγt expression is induced specifically under Th17 differentiation condition. Once expressed, RORγt in turn binds to the loci of Th17 signature genes Il17a and Il17f and up-regulates their expression (4) . Several small-molecule RORγt antagonists were identified that can inhibit Th17 cell differentiation and effector function (5) (6) (7) (8) . These findings suggested that RORγt inhibitors could be developed for treatment of autoimmune diseases. However, RORγt is also known for its critical role in promoting survival of CD4 + CD8 + double-positive (DP) thymocytes. A recent study showed that RORγt inhibitor treatment leads to not only reduced DP thymocyte numbers but also limited T cell repertoire diversity (9) . Therefore, it is still a challenge to develop a safe strategy to inhibit RORγt activity in Th17 cells in vivo.
Beyond their critical roles in Th17 cell differentiation, members of the ROR family are known to be key players in the circadian regulatory machinery, where they function as transcriptional activators to turn on the expression of circadian genes (10, 11) . In the circadian system, RORs' transcriptional activity is opposed by a pair of repressors, REV-ERBα and REV-ERBβ. Like RORs, REV-ERBs are also members of the nuclear hormone receptor family and play critical roles in circadian and metabolic regulations (12) . REV-ERBs recognize the same RORE DNA sequence as RORs and function as transcriptional repressors to suppress the expression of ROR target genes (13, 14) . Although the antagonistic relationship between ROR and REV-ERB was well established in the circadian rhythm system, it is not clear if a similar interaction exists in the T cell lineage.
In this study, we show that REV-ERBα is also a key feedback regulator of RORγt in Th17 cells. REV-ERBα is specifically upregulated during Th17 differentiation and plays a dual role in Th17 cells. When expressed at a low level, REV-ERBα promotes RORγt expression via the suppression of negative regulator NFIL3 as reported previously (15, 16) . At high expression level, REV-ERBα directly competes with RORγt binding to the loci of Th17 signature genes and suppresses Th17 effector function. Elevated REV-ERBα activity also ameliorates Th17-driven autoimmune disease experimental autoimmune encephalomyelitis (EAE). Our results suggest that modulating REV-ERBα activity could provide a way to manipulate Th17 cells in autoimmune diseases.
Results
REV-ERBα Is Highly Expressed during Th17 Cell Differentiation. In an effort to identify novel players in the nuclear hormone receptor superfamily that are involved in T cell function, we conducted expression profiling of nuclear hormone receptors in different T Significance Th17 cells are a subset of T cells that produce interleukin 17 and other proinflammatory cytokines. They are involved in the development of autoimmune diseases such as multiple sclerosis and rheumatoid arthritis. Previous studies illustrated that RORγt is a driver for Th17 cell differentiation. Here, we reveal REV-ERBα as an antagonist of RORγt. REV-ERBα and RORγt share the same DNA binding motif. REV-ERB can inhibit the expression of RORγt target genes and suppress RORγt-driven Th17 cell differentiation. Treatment with a synthetic REV-ERB agonist delays the onset and impedes the progression of experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple sclerosis. Taken together, our study suggests that modulating REV-ERBα activity may be used to manipulate Th17 cells in autoimmune diseases. helper cell subsets. We noticed that, similar to RORγt, REV-ERBα expression was uniquely up-regulated in Th17 cells at both mRNA and protein levels ( Fig. 1 A-C). The differences in the kinetics of REV-ERBα mRNA and protein expression are likely due to a tightly regulated protein degradation pathway of REV-ERBα (17, 18) . Furthermore, REV-ERBα expression was significantly higher in human Th17 cells relative to Th1 cells (Fig. 1D ). The unique expression pattern of REV-ERBα suggested that it may play a role in the regulation of Th17 cells. Previous studies on circadian regulation demonstrated that, by binding to the same RORE motifs, RORs activate transcription of their target genes, whereas REV-ERBs act as repressors of the same targets (13, 14) . We hypothesized that REV-ERBs may suppress Th17 cell differentiation and function by antagonizing RORγt.
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Ectopic Expression of REV-ERBα Inhibits the Expression of Th17
Signature Genes. To assess the role of REV-ERBs in Th17 cells, we examined the effects of ectopic expression of REV-ERBs on Th1 and Th17 cell differentiation. Retroviral expression of REV-ERBα during Th17 differentiation significantly suppressed interleukin-17A (IL-17A) production compared to T cells transduced with control vector MIGR1 (Fig. 1E ). The inhibitory effect of REV-ERBα is specific to Th17 cells, as it did not suppress interferon (IFN)-γ expression in Th1 cells. Ectopic expression of REV-ERBβ showed a modest negative impact on Th17 cells ( Fig. 1E ). Th17 differentiation can also be driven by ectopic expression of RORγt in T cells cultured without Th17 polarizing cytokines (3) . We found that coexpression of REV-ERBα along with RORγt also led to significant decrease of IL-17A expression (SI Appendix, Fig. S1 ), suggesting that REV-ERBα can suppress RORγt-dependent IL-17A expression. To evaluate the genome-wide effects of REV-ERBs' ectopic expression in Th17 cells, we performed RNA-sequencing (RNA-seq) analysis of Th17 cells retrovirally transduced with REV-ERBα, REV-ERBβ, or MIGR1 control vector (19) . KEGG pathway analysis of the differentially expressed genes indicated that REV-ERBα regulates genes involved in T cell receptor signaling, cytokine/chemokine signaling, as well as circadian rhythm regulation ( Fig. 1F ). REV-ERBα-transduced cells differentially expressed a number of Th17 cell signature genes compared with MIGR1-transduced cells, which include Il17a, Il17f, Il23r, Csf2, and Tgfb3. Interestingly, most of these genes were significantly down-regulated by REV-ERBα ( Fig. 1G ). REV-ERBβ expression also suppressed most Th17 signature genes, but its impact was modest compared to REV-ERBα ( Fig.  1G ). Therefore, we decided to focus on the role of REV-ERBα in suppressing Th17 cell differentiation and the expression of Th17 signature genes. 2C ). These findings suggest that REV-ERBα can directly repress Il17a expression by binding to the Il17a CNS5 enhancer.
To identify genome-wide REV-ERBα target genes in Th17 cells, we performed REV-ERBα ChIP-seq assays (23) . As expected, the de novo REV-ERBα binding motif is highly similar to the established RORγt binding motif (Fig. 2D ). When compared to previously published RORγt ChIP-seq data, about 30% of the 8,884 REV-ERBα binding sites in Th17 cells are also RORγt binding sites ( Fig. 2E) (4) . It is expected that a large proportion of REV-ERBα binding peaks are different from RORγt binding peaks despite their shared binding motif. This is partly due to the finding that REV-ERBα can target DNA indirectly by interacting with other transcription factors (24) . KEGG pathway analysis of genes bound by both REV-ERBα and RORγt revealed that they are enriched with genes involved in T cell signal and cytokine/chemokine pathways (Fig.  2F ). In addition to Il17a, several other Th17 cell signature genes, including Il17f, Il23r, and Tgfb3, were also identified as direct targets of REV-ERBα ( Fig. 2 E and G and SI Appendix, Fig. S2 ). The finding that REV-ERBα binds to a large number of RORγt target genes suggests that REV-ERBα inhibits Th17 cell differentiation through direct suppression of the expression of key Th17 cell signature genes. To further test this hypothesis, we examined whether ectopic REV-ERBα expression decreases the binding of RORγt to Il17a by ChIP-qPCR. Indeed, RORγt binding at the Il17a locus decreased significantly in cells transduced with a REV-ERBα expressing retroviral vector (Fig. 2H) . Conversely, ectopic expression of RORγt diminished REV-ERBα binding at the Il17a locus (Fig. 2I ).
In Vivo Induction of REV-ERBα Expression in T Cells Suppresses EAE
Disease Progression. Since high levels of REV-ERBα expression are inhibitory to Th17 cell differentiation in vitro, we explored whether constitutive REV-ERBα expression in T cells could ameliorate Th17 cell-mediated autoimmune diseases in vivo. We tested this hypothesis in EAE, a mouse model for multiple sclerosis, as Th17 cells play a critical role in EAE disease development. A tetracycline-inducible REV-ERBα transgenic mouse (TRE-REV-ERBα/Rosa-M2rtTA) (25) was crossed with a 2D2 TCR transgenic mouse, which carries a TCR that recognizes the MOG (myelin oligodendrocyte glycoprotein) peptide (26) , to generate a triple transgenic mouse strain (TTg). T cells from the TTg mice express REV-ERBα constitutively under doxycycline treatment in vivo (SI Appendix, Fig. S3A ). CD4 + T cells from the TTg mice were activated in vitro under Th17 conditions for 4 d before being adoptively transferred into WT recipient mice to induce EAE. Mice were given doxycycline water to induce REV-ERBα expression in transferred 2D2 T cells or normal water. The doxycycline-treated group showed delayed EAE disease onset as well as slower disease progression compared to mice that were given normal water (Fig. 3A) . Elevated REV-ERBα expression did not affect homing, proliferation, or survival of the transferred CD4 + T cells (SI Appendix, Fig. S3B ). However, consistent with milder disease progression observed in mice treated with doxycycline, the frequency of IL-17A producing 2D2 T cells were significantly reduced in the CNS tissues of these mice compared to controls (Fig. 3B ). Histopathology analysis showed that doxycycline treatment significantly reduced inflammation levels with a decreasing trend for demyelination in the spinal cord of these mice ( Fig. 3 C and D) . These differences were dependent on REV-ERBα induction because the same doxycycline treatment of mice transferred with WT 2D2 T cells did not delay or ameliorate EAE disease progression (SI Appendix, Fig. S3C ). Thus, elevated expression of REV-ERBα in T cells can attenuate Th17 cellmediated EAE.
REV-ERBα Deficiency Impairs Th17 Cell Differentiation. Despite the suppressive role of REV-ERBα on the expression of Th17 signature genes, a previous study by Hooper and coworkers (15) showed that REV-ERBα-deficient T cells were also defective in Th17 differentiation. It was proposed that in the absence of REV-ERBα, expression of NFIL3 increases, which, in turn, suppresses Th17 cell development by directly binding to the RORγt promoter and repressing its expression. We assessed the effect of REV-ERB ablation in Th17 cell differentiation and function. The REV-ERBα/β knockout T cells showed a moderate reduction in Th17 differentiation measured by IL-17A expression ( Fig. 4A) , consistent with the findings by Hooper's group. To test the impact of REV-ERB deletion in vivo, we utilized T cell-specific REV-ERBα/β conditional knockout mice (REV-ERBα fl/fl /β fl/fl CD4Cre) (14) . The REV-ERB conditional knockout mice and WT controls were immunized with MOG/ CFA to induce EAE. Disease development was monitored for 3 wk and followed by analysis of T cell composition in CNS tissues. Mice carrying REV-ERB null T cells developed milder EAE accompanied with reduced IL-17A-producing T cells in the CNS tissues ( Fig. 4 B and C) . These results suggest that REV-ERBα expression needs to be tightly regulated for robust Th17 cell differentiation. Insufficient REV-ERBα activity leads to decreased Th17 cell differentiation due to increased levels of NFIL3, which suppress RORγt expression, whereas at high levels REV-ERBα outcompetes RORγt for regulatory binding sites in Th17 signature genes such as Il17a and Il17f, also resulting in the suppression of Th17 cell differentiation. It is worth noting that overexpression of REV-ERBα exerts a much stronger inhibitory effect on Th17 cells than absence of REV-ERBα expression (Figs. 1E and 4A).
A Synthetic Agonist of REV-ERBα Can Inhibit Th17 Cell Differentiation
In Vitro and Ameliorate EAE In Vivo. Structural studies have shown that REV-ERBs contain a ligand binding domain, and their activity can be modulated by specific ligands (27) . Heme, the prosthetic group in hemoglobin, was identified as an endogenous agonist that binds to REV-ERBs and potentiates their activity (28, 29) . Efforts have also been made to generate synthetic REV-ERB agonists with higher specificity and fewer side effects. Two chemical compounds, SR9009 and SR9011, bind specifically to REV-ERBs and modulate their activity, and exhibited favorable pharmacokinetic properties when tested in mice (30) (31) (32) . Since increased REV-ERBα expression suppresses Th17 cell differentiation and function, we tested if potentiating REV-ERB activity via agonist treatment could have a similar effect on Th17 cells. First, we cultured naïve mouse CD4 T cells under Th1, Th17, or iTreg differentiation conditions with or without SR9009. SR9009 treatment significantly inhibited Th17 cell differentiation but did not affect Th1 or iTreg differentiation ( Fig. 5 A and B) . Similarly, Th17, but not Th1, differentiation of human CD4 T cells was significantly inhibited by SR9009 treatment (Fig. 5C) . To test the specificity of SR9009, we cultured CD4 T cells isolated from REV-ERBα/β conditional knockout and WT control mice under Th17 differentiation condition with or without SR9009 and measured their IL-17A expression. While Th17 differentiation of WT T cells was suppressed by SR9009 treatment, IL-17A expression in REV-ERB null T cells was not affected ( Fig. 5 D and E) . These results suggest that SR9009 can inhibit Th17 differentiation by modulating REV-ERB activity. To investigate the molecular mechanism of SR9009's effect in Th17 cells, we examined the recruitment of NCoR, a corepressor that binds to REV-ERB and represses its target gene expression (24) . ChIP-qPCR assay showed that NCoR recruitment to the Il17a CNS5 enhancer increased significantly in the presence of SR9009, indicating that SR9009 can target the IL17A pathway directly via enhancing NCoR:REV-ERB interaction at the Il17a locus (Fig. 5F) .
The inhibitory effect of SR9009 on Th17 differentiation in vitro compelled us to test if it could also exert similar modulating effect on Th17-induced autoimmune diseases in vivo. Unlike RORγt antagonists, SR9009 treatment did not skew T cell development in the thymus or grossly affect T cell activation state in the periphery (SI Appendix, Fig. S4) .
To test the effect of SR9009 treatment in mouse EAE models, we immunized C57/BL6 mice with MOG/CFA and started injection of SR9009 or vehicle control 7 d after initial immunization. Mice treated with SR9009 showed significantly delayed onset and slower progression of EAE compared to vehicle-treated control group (Fig. 5G ). SR9009 treatment also reduced the frequency of IL-17A-producing CD4 T cells infiltrating the CNS tissues during EAE (Fig. 5H) . We next explored the efficacy of REV-ERB agonist treatment on mice that have already developed EAE. We induced EAE in SJL mice, which upon PLP (myelin proteolipid protein) peptide immunization, exhibit disease progression in remitting and relapsing patterns mimicking the development of multiple sclerosis in humans. SR9009 treatment of SJL mice during the primary phase of EAE showed inhibitory effects similar to its effects in C57/BL6 mice (data not shown). When SR9009 was administered in the remitting phase, SR9009-treated mice maintained their remitting state, whereas vehicle-treated control mice developed additional episodes of EAE symptoms (Fig. 5I) . Furthermore, the frequency of IL-17A-producing CD4 T cells was also significantly reduced in the CNS tissues of SR9009-treated mice compared to controls (Fig. 5J) . These results demonstrate that modulating in vivo REV-ERB activity by its agonist SR9009 effectively suppresses development and progression of Th17 cellmediated EAE.
Discussion
In this study, we demonstrated a role for REV-ERBα in the regulation of Th17 cell differentiation and function in addition to its established roles in circadian rhythm and metabolism. REV-ERBα is induced during Th17 cell differentiation and directly competes with RORγt by binding to the RORE sites to repress the expression of key Th17 cell signature genes such as Il17a and Il17f. At the same time, normal RORγt induction is also dependent on repression of Nfil3 by REV-ERBα (15) . This is substantiated by reduction of IL-17A production in vitro and milder EAE phenotype in vivo as a result of T cell-specific REV-ERB ablation. These observations suggest that REV-ERBα serves as a feedback regulator for RORγt in T cells, and its expression needs to stay at the right level for optimal Th17 differentiation.
A recent study by Amir et al. reported similar results showing reduced Th17 activity when REV-ERB expression is increased (33) . However, the same study also showed Th17 differentiation was enhanced in REV-ERBα knockout T cells, which differs from our results and the study performed by Yu et al. (15) . One primary difference between the 2 studies is that T cell-specific REV-ERB conditional knockout mice were used in our study, while REV-ERBα germline knockout mice were used in the study by Amir et al. Since REV-ERBα germline knockout mice carried severe defects in circadian and metabolic regulation, it is possible that these perturbations originated outside of the immune system rendered T cells more inflammatory under Th17-inducing conditions. Additionally, differences in gut microbiota between mouse facilities might also contribute to the contradictory results.
Given the key role REV-ERBα plays in Th17 cells, we explored if tuning REV-ERBα activity can influence Th17 differentiation and function. Our results showed that elevated REV-ERBα expression in T cells or treatment with REV-ERB ligand SR9009 suppresses Th17 cell differentiation in vitro and inhibits the development of EAE in vivo. Although specific REV-ERBα induction in T cells is sufficient to ameliorate EAE, SR9009 treatment in mice might also impact non-Th17 cells. A previous study demonstrated that REV-ERBα could suppress macrophage expression of IL-6, a key cytokine for Th17 cell differentiation (34) . We also observed that subsets of gamma/delta T cells and regulatory T cells could express high levels of REV-ERBα, although the significance of these cell subsets in EAE pathogenesis is currently unclear and requires further characterization. A recent study raised concern on the specificity of SR9009 by demonstrating that SR9009 could exert REV-ERB independent effects in certain tissues, such as mouse embryonic stem cells and hepatocytes (35) . In our experiments, SR9009 treatment only affects Th17 differentiation in WT T cells, not REV-ERBα/β double knockout T cells ( Fig. 5 D and E) , suggesting that SR9009s inhibitory effects on Th17 cells is REV-ERB dependent.
A concerted effort has been made to identify RORα/γ antagonists for treatment of Th17-related autoimmune diseases (5) (6) (7) (8) .
In fact, a recent clinical trial on an RORγ antagonist showed encouraging results in psoriasis patients (36) . In addition to Th17 cells, RORγt is also highly expressed in developing T cells in the thymus. A recent report showed that RORγ antagonist treatment leads to DP thymocyte apoptosis and reshapes the T cell repertoire by skewing TCRα rearrangement (9) . Although limiting the diversity of the T cell repertoire could be beneficial in some autoimmune disease settings, its long-term effect could also increase the risk to cancer and certain infections. In contrast to RORγt, the low expression levels of REV-ERBα and REV-ERBβ in thymocytes and our own results (SI Appendix, Fig. S4 ) suggest that REV-ERB agonists will not likely have the same impact on thymocytes and the T cell repertoire as RORγ antagonists (37) . Therefore, a strategy of targeting REV-ERB alone or in combination with RORγ may provide a unique advantage in developing treatments for Th17 cell-mediated autoimmune diseases.
Materials and Methods
Mice. Rosa-M2rtTA, TRE-REV-ERBα, and 2D2 transgenic mice were purchased from Jackson Laboratory. The 3 transgenic lines were crossed to generate Rosa-M2rtTAxTRE-RVBx2D2 triple transgenic mice. REV-ERBα fl/fl /β fl/fl mice were generated previously (14) . CD4Cre transgenic, C57BL/6, SJL/J, and Ly5.1 + congenic mice were purchased from the Jackson Laboratory. All mice were maintained in the Salk Institute specific pathogen free (SPF) animal facility in accordance with the protocols approved by the Institutional Animal Care and Use Committee (IACUC) at the Salk Institute.
Reverse Transcription and Quantitative PCR. Total RNA was isolated from CD4 T cells using TRIzol reagent (Life Technologies). cDNA was synthesized with iScript Reverse Transcription Supermix for RT-qPCR (Bio-Rad), followed by qPCR using SYBR Green PCR Master Mix (Applied Biosystems). Quantitative PCR was performed on an Applied Biosystems ViiA 7 Real-Time PCR System with gene specific primers listed in SI Appendix, Table S1 . Retroviral Transduction. HEK 293T cells were transfected via FuGENE6 reagent (Promega), which contained 0.8 μg of pCL-Eco retroviral packaging plasmid and 1.2 μg of expression plasmid. pCL-Eco was a gift from Inder Verma (Salk Institute, La Jolla, CA) (38) . Viral supernatant was harvested 48 and 72 h after transfection. CD4 + T cells were cultured in Th17 polarizing condition and retroviral transduction was performed 24 and 48 h after activation by incubating cells with viral supernatant in the presence of polybrene (4 μg/mL; Millipore) and centrifuged at 2,500 rpm for 90 min at 32°C.
ChIP. Naive CD4 + T cells were activated and polarized in Th17 condition for 3 d for ChIP experiments as described previously (14) . Mouse IgG control antibody was purchased from Santa Cruz Biotechnology. RORγt ChIP was performed with a combination of antibodies from BioLegend and Santa Cruz Biotechnologies. REV-ERBα antibody was generated as previously described (14) . NCoR1 antibody was purchased from Cell Signaling. Primers spanning the regulatory regions of Il17a, Cry1, and Gmpr are described in SI Appendix, Table S2 .
ChIP-Seq and Data Analysis. ChIP-seq libraries were constructed and sequenced as described previously (14) . Reads were aligned against the mouse mm9 reference genome using the Bowtie2 aligner with standard parameters that allow up to 2 mismatches in the read. Peak calling, motif analyses, and other data analysis were performed using HOMER, a software suite for ChIPseq analysis as described previously (14) . Visualization of ChIP-Seq results was achieved by uploading custom tracks onto the University of California, Santa Cruz (UCSC) genome browser. ChIP-seq data can be accessed in the National Center for Biotechnology Information (NCBI) GEO database under the accession no. GSE72271.
RNA-Seq and Data Analysis. RNA-seq libraries were prepared from 100 ng of total RNA (TrueSeq v2, Illumina) and single-ended sequencing was performed on the Illumina HiSeq 2500. Read alignment and junction finding was accomplished using STAR (39) and differential gene expression with Cuffdiff 2 (40) . Student's t test was performed to generate a list of differentially expressed genes (P < 0.05), which was then run through KEGG pathway analysis on DAVID (41, 42) to examine enriched functional groups. Heatmaps were generated on Matrix2png (43) . RNA-seq data can be accessed in the NCBI Sequence Read Archive under accession no. SRP062715.
EAE Models. For active EAE, mice were immunized s.c. with 200 ng of MOG (35-55) peptide (BL6 mice) or PLP (139-151) peptide (SJL mice) in CFA and received 200 ng of Pertussis toxin intraperitoneally on days 0 and 2. Mice were monitored daily for disease progression. At the end point, the brain and spinal cord were harvested for histology and immune cell profiling. For passive EAE, CD4 T cells from Rosa-M2rtTAxTRE-RVBx2D2 mice were activated under Th17 condition for 3 d, then restimulated overnight in the presence of IL-18 (20 ng/mL; Fisher Scientific). Two to 3 million T cells were adoptively transferred into WT recipient mice, which were given normal water or Doxycycline water to induce REV-ERBα expression. EAE disease progression was monitored as in the active EAE model.
